Alpine is committed to bringing innovative new drug therapies to patients with serious or life-threatening diseases or conditions.
A Study of Povetacicept in Adult Healthy Volunteers
The goal of this study was to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of povetacicept.
An Open-Label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
The goal of this open-label clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with autoimmune kidney disease to determine if povetacicept is safe and potentially beneficial in treating these diseases.
An Open-label Study of Povetacicept (ALPN-303) in Subjects With Autoimmune Cytopenias
The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases.
A Randomized, Double-Blind, Placebo-Controlled Study of ALPN-101 in Systemic Lupus Erythematosus
The goal of this multinational, randomized, blinded study is to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept (ALPN-101) in adults with moderate to severe active systemic lupus erythematosus (SLE).
Learn more about the acazicolcept studies from the 2019 ASH Annual Meeting and 2020 EULAR E-Congress.
Alpine is committed to bringing innovative new drug therapies to patients with serious or life-threatening diseases or conditions. Participation in a clinical trial is currently the most appropriate way to access our investigational therapies.
In line with the 21st Century Cures Act (Pub.L. 114-255), Alpine may revise this policy at any time.
- Learn about the FDA’s position on expanded access
- Find out more about Alpine’s clinical trials
- Search enrolling clinical trials for a specific medicine or disease at ClinicalTrials.gov